Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 518 entries
Sorted by: Best Match Show Resources per page
Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n).

Journal of young pharmacists : JYP

Mahesh R, Bhatt S, Devadoss T, Jindal A, Gautam B, Pandey D.
PMID: 23493308
J Young Pharm. 2012 Oct;4(4):235-44. doi: 10.4103/0975-1483.104367.

The present study was designed to evaluate the antidepressant potential of 5-HT3 receptor antagonist N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). The compound '6n' with optimum log P and pA 2 value identified from a series of compounds synthesized in our laboratory was subjected...

Cite
Mahesh R, Bhatt S, Devadoss T, et al. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm. 2012;4(4):235-44doi: 10.4103/0975-1483.104367.
Mahesh, R., Bhatt, S., Devadoss, T., Jindal, A., Gautam, B., & Pandey, D. (2012). Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n). Journal of young pharmacists : JYP, 4(4), 235-44. https://doi.org/10.4103/0975-1483.104367
Mahesh, R, et al. "Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n)." Journal of young pharmacists : JYP vol. 4,4 (2012): 235-44. doi: https://doi.org/10.4103/0975-1483.104367
Mahesh R, Bhatt S, Devadoss T, Jindal A, Gautam B, Pandey D. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm. 2012 Oct;4(4):235-44. doi: 10.4103/0975-1483.104367. PMID: 23493308; PMCID: PMC3573375.
Copy Download .nbib Format: NLM
Effect of Radix Sophorae Tonkinensis on the activity of cytochrome P450 isoforms in rats.

International journal of clinical and experimental medicine

Cai J, Ma J, Xu K, Gao G, Xiang Y, Lin C.
PMID: 26309650
Int J Clin Exp Med. 2015 Jun 15;8(6):9737-43. eCollection 2015.

Radix Sophorae Tonkinensis (S. tonkinensis) is the processed lateral root of Sophora subprostrata (Leguminosae) that widely distributed over the southwest China. Radix Sophorae Tonkinensis has been widely used as a Chinese medicinal herb for the treatment of disease such...

Cite
Cai J, Ma J, Xu K, et al. Effect of Radix Sophorae Tonkinensis on the activity of cytochrome P450 isoforms in rats. Int J Clin Exp Med. 2015;8(6):9737-43
Cai, J., Ma, J., Xu, K., Gao, G., Xiang, Y., & Lin, C. (2015). Effect of Radix Sophorae Tonkinensis on the activity of cytochrome P450 isoforms in rats. International journal of clinical and experimental medicine, 8(6), 9737-43.
Cai, Jinzhang, et al. "Effect of Radix Sophorae Tonkinensis on the activity of cytochrome P450 isoforms in rats." International journal of clinical and experimental medicine vol. 8,6 (2015): 9737-43.
Cai J, Ma J, Xu K, Gao G, Xiang Y, Lin C. Effect of Radix Sophorae Tonkinensis on the activity of cytochrome P450 isoforms in rats. Int J Clin Exp Med. 2015 Jun 15;8(6):9737-43. eCollection 2015. PMID: 26309650; PMCID: PMC4538074.
Copy Download .nbib Format: NLM
Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report.

Clinical practice and epidemiology in mental health : CP & EMH

Dehning J, Grunze H, Hausmann A.
PMID: 28659991
Clin Pract Epidemiol Ment Health. 2017 May 31;13:43-48. doi: 10.2174/1745017901713010043. eCollection 2017.

BACKGROUND: The optimal duration of antidepressant treatment in bipolar depression appears to be controversial due to a lack of quality evidence, and guideline recommendations are either vague or contradictive. This is especially true for second line treatments such as...

Cite
Dehning J, Grunze H, Hausmann A. Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report. Clin Pract Epidemiol Ment Health. 2017;13:43-48doi: 10.2174/1745017901713010043.
Dehning, J., Grunze, H., & Hausmann, A. (2017). Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report. Clinical practice and epidemiology in mental health : CP & EMH, 1343-48. https://doi.org/10.2174/1745017901713010043
Dehning, Julia, et al. "Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report." Clinical practice and epidemiology in mental health : CP & EMH vol. 13 (2017): 43-48. doi: https://doi.org/10.2174/1745017901713010043
Dehning J, Grunze H, Hausmann A. Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report. Clin Pract Epidemiol Ment Health. 2017 May 31;13:43-48. doi: 10.2174/1745017901713010043. eCollection 2017. PMID: 28659991; PMCID: PMC5470062.
Copy Download .nbib Format: NLM
Weight loss medications in Canada - a new frontier or a repeat of past mistakes?.

Diabetes, metabolic syndrome and obesity : targets and therapy

Wharton S, Lee J, Christensen RA.
PMID: 29042804
Diabetes Metab Syndr Obes. 2017 Oct 04;10:413-417. doi: 10.2147/DMSO.S141571. eCollection 2017.

Current methods for the treatment of excess weight can involve healthy behavior changes, pharmacotherapy, and surgical interventions. Many individuals are able to lose some degree of weight through behavioral changes; however, they are often unable to maintain their weight...

Cite
Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes Metab Syndr Obes. 2017;10:413-417doi: 10.2147/DMSO.S141571.
Wharton, S., Lee, J., & Christensen, R. A. (2017). Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes, metabolic syndrome and obesity : targets and therapy, 10413-417. https://doi.org/10.2147/DMSO.S141571
Wharton, Sean, et al. "Weight loss medications in Canada - a new frontier or a repeat of past mistakes?." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 413-417. doi: https://doi.org/10.2147/DMSO.S141571
Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes Metab Syndr Obes. 2017 Oct 04;10:413-417. doi: 10.2147/DMSO.S141571. eCollection 2017. PMID: 29042804; PMCID: PMC5633321.
Copy Download .nbib Format: NLM
How Relevant is Food Craving to Obesity and Its Treatment?.

Frontiers in psychiatry

Potenza MN, Grilo CM.
PMID: 25477827
Front Psychiatry. 2014 Nov 19;5:164. doi: 10.3389/fpsyt.2014.00164. eCollection 2014.

No abstract available.

Cite
Potenza MN, Grilo CM. How Relevant is Food Craving to Obesity and Its Treatment?. Front Psychiatry. 2014;5:164doi: 10.3389/fpsyt.2014.00164.
Potenza, M. N., & Grilo, C. M. (2014). How Relevant is Food Craving to Obesity and Its Treatment?. Frontiers in psychiatry, 5164. https://doi.org/10.3389/fpsyt.2014.00164
Potenza, Marc N, and Grilo, Carlos M. "How Relevant is Food Craving to Obesity and Its Treatment?." Frontiers in psychiatry vol. 5 (2014): 164. doi: https://doi.org/10.3389/fpsyt.2014.00164
Potenza MN, Grilo CM. How Relevant is Food Craving to Obesity and Its Treatment?. Front Psychiatry. 2014 Nov 19;5:164. doi: 10.3389/fpsyt.2014.00164. eCollection 2014. PMID: 25477827; PMCID: PMC4237037.
Copy Download .nbib Format: NLM
The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Hou YC, Lai CH.
PMID: 26598593
Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):319-20. doi: 10.9758/cpn.2015.13.3.319.

The impacts from the bupropion on the brain structures have seldom been mentioned in the literature. The bupropion is a kind of antidepressant with dual action in the norepinephrine and dopamine receptors. Here we have a case to share...

Cite
Hou YC, Lai CH. The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment. Clin Psychopharmacol Neurosci. 2015;13(3):319-20doi: 10.9758/cpn.2015.13.3.319.
Hou, Y. C., & Lai, C. H. (2015). The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 13(3), 319-20. https://doi.org/10.9758/cpn.2015.13.3.319
Hou, Yi-Cheng, and Lai, Chien-Han. "The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 13,3 (2015): 319-20. doi: https://doi.org/10.9758/cpn.2015.13.3.319
Hou YC, Lai CH. The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment. Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):319-20. doi: 10.9758/cpn.2015.13.3.319. PMID: 26598593; PMCID: PMC4662168.
Copy Download .nbib Format: NLM
Stimulants for the Control of Hedonic Appetite.

Frontiers in pharmacology

Poulton AS, Hibbert EJ, Champion BL, Nanan RK.
PMID: 27199749
Front Pharmacol. 2016 Apr 25;7:105. doi: 10.3389/fphar.2016.00105. eCollection 2016.

The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive...

Cite
Poulton AS, Hibbert EJ, Champion BL, et al. Stimulants for the Control of Hedonic Appetite. Front Pharmacol. 2016;7:105doi: 10.3389/fphar.2016.00105.
Poulton, A. S., Hibbert, E. J., Champion, B. L., & Nanan, R. K. (2016). Stimulants for the Control of Hedonic Appetite. Frontiers in pharmacology, 7105. https://doi.org/10.3389/fphar.2016.00105
Poulton, Alison S, et al. "Stimulants for the Control of Hedonic Appetite." Frontiers in pharmacology vol. 7 (2016): 105. doi: https://doi.org/10.3389/fphar.2016.00105
Poulton AS, Hibbert EJ, Champion BL, Nanan RK. Stimulants for the Control of Hedonic Appetite. Front Pharmacol. 2016 Apr 25;7:105. doi: 10.3389/fphar.2016.00105. eCollection 2016. PMID: 27199749; PMCID: PMC4843092.
Copy Download .nbib Format: NLM
Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.

P & T : a peer-reviewed journal for formulary management

Sherman MM, Ungureanu S, Rey JA.
PMID: 26957883
P T. 2016 Mar;41(3):164-72.

Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.

Cite
Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. P T. 2016;41(3):164-72
Sherman, M. M., Ungureanu, S., & Rey, J. A. (2016). Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. P & T : a peer-reviewed journal for formulary management, 41(3), 164-72.
Sherman, Matthew M, et al. "Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults." P & T : a peer-reviewed journal for formulary management vol. 41,3 (2016): 164-72.
Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. P T. 2016 Mar;41(3):164-72. PMID: 26957883; PMCID: PMC4771085.
Copy Download .nbib Format: NLM
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

American journal of neurodegenerative disease

Lauterbach EC.
PMID: 27073741
Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016.

Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of...

Cite
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016;5(1):29-51
Lauterbach, E. C. (2016). Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. American journal of neurodegenerative disease, 5(1), 29-51.
Lauterbach, Edward C. "Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease." American journal of neurodegenerative disease vol. 5,1 (2016): 29-51.
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016. PMID: 27073741; PMCID: PMC4788730.
Copy Download .nbib Format: NLM
Evaluation of the impact of Flos Daturae on rat hepatic cytochrome P450 enzymes by cocktail probe drugs.

International journal of clinical and experimental medicine

Geng P, Wang S, Wang C, Chen J, Zhang L, Yang S, Wen C, Zhou Y, Zhang M.
PMID: 26885208
Int J Clin Exp Med. 2015 Dec 15;8(12):22310-8. eCollection 2015.

Flos Daturae, known as "baimantuoluo" or "yangjinhua" in China, has been used for centuries in Traditional Chinese Medicine for the treatment of asthma, convulsions, pain, and rheumatism. To investigate the influences of Flos Daturae on the activities of rat...

Cite
Geng P, Wang S, Wang C, et al. Evaluation of the impact of Flos Daturae on rat hepatic cytochrome P450 enzymes by cocktail probe drugs. Int J Clin Exp Med. 2015;8(12):22310-8
Geng, P., Wang, S., Wang, C., Chen, J., Zhang, L., Yang, S., Wen, C., Zhou, Y., & Zhang, M. (2015). Evaluation of the impact of Flos Daturae on rat hepatic cytochrome P450 enzymes by cocktail probe drugs. International journal of clinical and experimental medicine, 8(12), 22310-8.
Geng, Peiwu, et al. "Evaluation of the impact of Flos Daturae on rat hepatic cytochrome P450 enzymes by cocktail probe drugs." International journal of clinical and experimental medicine vol. 8,12 (2015): 22310-8.
Geng P, Wang S, Wang C, Chen J, Zhang L, Yang S, Wen C, Zhou Y, Zhang M. Evaluation of the impact of Flos Daturae on rat hepatic cytochrome P450 enzymes by cocktail probe drugs. Int J Clin Exp Med. 2015 Dec 15;8(12):22310-8. eCollection 2015. PMID: 26885208; PMCID: PMC4729994.
Copy Download .nbib Format: NLM
Therapy for Cessation of Smoking.

Medical journal, Armed Forces India

Bhattacharyya D, Rai SP, Neog LS.
PMID: 27408159
Med J Armed Forces India. 2008 Jul;64(3):254-9. doi: 10.1016/S0377-1237(08)80107-4. Epub 2011 Jul 21.

Tobacco dependence is a chronic relapsing medical illness. Unfortunately more than 1.1 billion people worldwide smoke tobacco. Tobacco consumption rate is very high in India. Providing three minutes counseling by physicians doubles the cessation rate as compared to no...

Cite
Bhattacharyya D, Rai SP, Neog LS. Therapy for Cessation of Smoking. Med J Armed Forces India. 2011;64(3):254-9doi: 10.1016/S0377-1237(08)80107-4.
Bhattacharyya, D., Rai, S. P., & Neog, L. S. (2008). Therapy for Cessation of Smoking. Medical journal, Armed Forces India, 64(3), 254-9. https://doi.org/10.1016/S0377-1237(08)80107-4
Bhattacharyya, D, et al. "Therapy for Cessation of Smoking." Medical journal, Armed Forces India vol. 64,3 (2008): 254-9. doi: https://doi.org/10.1016/S0377-1237(08)80107-4
Bhattacharyya D, Rai SP, Neog LS. Therapy for Cessation of Smoking. Med J Armed Forces India. 2008 Jul;64(3):254-9. doi: 10.1016/S0377-1237(08)80107-4. Epub 2011 Jul 21. PMID: 27408159; PMCID: PMC4921594.
Copy Download .nbib Format: NLM
Strategies to promote smoking cessation among adolescents.

Paediatrics & child health

Harvey J, Chadi N.
PMID: 27429574
Paediatr Child Health. 2016 May;21(4):201-8. doi: 10.1093/pch/21.4.201.

In recent years, youth have been exposed to a broader spectrum of tobacco products including smokeless tobacco, hookah (water pipe) and e-cigarettes. Despite active local, provincial/territorial and national prevention strategies and legislated controls, thousands of teenagers develop an addiction...

Cite
Harvey J, Chadi N. Strategies to promote smoking cessation among adolescents. Paediatr Child Health. 2016;21(4):201-8doi: 10.1093/pch/21.4.201.
Harvey, J., & Chadi, N. (2016). Strategies to promote smoking cessation among adolescents. Paediatrics & child health, 21(4), 201-8. https://doi.org/10.1093/pch/21.4.201
Harvey, Johanne, and Chadi, Nicholas. "Strategies to promote smoking cessation among adolescents." Paediatrics & child health vol. 21,4 (2016): 201-8. doi: https://doi.org/10.1093/pch/21.4.201
Harvey J, Chadi N. Strategies to promote smoking cessation among adolescents. Paediatr Child Health. 2016 May;21(4):201-8. doi: 10.1093/pch/21.4.201. French. PMID: 27429574; PMCID: PMC4934162.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 518 entries